Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics - PubMed
4 days ago
- #Bispecific Antibodies
- #Precision Medicine
- #Cancer Immunotherapy
- Bispecific T cell engagers (TCEs) and higher-order multispecific immunotherapeutics are emerging as precision immune modulation approaches in cancer therapy.
- These engineered antibodies redirect immune effector cells toward tumor targets, enhancing antitumor immune responses.
- Clinical success has been notable in hematologic malignancies, but challenges remain in treating solid tumors.
- Recent preclinical advances focus on the design and optimization of TCEs and multispecific immune engager platforms.
- Key considerations in development include pharmacokinetics, safety, resistance, and manufacturing.
- The versatility of immune cell-redirecting immunotherapies is pivotal for the next generation of precision cancer therapy.